Isoptin

Verapamil Hydrochloride, the active ingredient in Isoptin, is a calcium channel blocker presented as an oral dosage form for oral use. It is indicated for patients requiring blood pressure control, relief of chest pain due to myocardial ischemia, and rhythm management in certain cardiac arrhythmias. It is employed to manage hypertension, angina pectoris, supraventricular tachycardia, and atrial fibrillation in adult patients.

GNH USA supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and global markets.

Isoptin (verapamil) is a calcium channel blocker indicated for several cardiovascular conditions.

Hypertension: lowers systemic vascular resistance to help control high blood pressure. Angina pectoris: reduces myocardial oxygen demand and improves coronary blood flow, relieving chest pain. Supraventricular tachycardia: slows atrioventricular nodal conduction to terminate rapid heart rhythms. Atrial fibrillation: assists in ventricular rate control by moderating AV‑node conduction.

Verapamil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Constipation: reduced gut motility causing hard stools. - Dizziness: transient light‑headedness, especially on standing. - Headache: mild to moderate cranial pain. - Flushing: warmth and redness of skin. - Peripheral edema: swelling of ankles or feet. - Nausea: upset stomach, sometimes with mild vomiting. - Fatigue: feeling of tiredness or reduced energy. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure drop that may cause fainting. - Bradycardia: abnormally slow heart rate needing medical review. - Heart block: impaired AV‑node electrical conduction. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Verapamil, clinicians should consider several precautionary measures to ensure patient safety.

Cardiovascular assessment: evaluate for existing heart block, severe left ventricular dysfunction, or hypotension before initiation. Concomitant beta‑blocker use: avoid excessive bradycardia by monitoring heart rate when combined with beta‑blockers. Drug interactions: review patient medications for CYP3A4 inhibitors or inducers that may alter verapamil levels. Renal/hepatic impairment: adjust therapy cautiously in patients with significant liver or kidney disease. Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetric specialist. Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Verapamil interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Beta‑blockers: combined use can cause severe bradycardia and AV‑node block. - Digoxin: verapamil raises digoxin concentrations, increasing risk of toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may markedly increase verapamil plasma levels. - Diltiazem or other non‑dihydropyridine calcium channel blockers: additive effects on cardiac conduction.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: concurrent therapy may enhance hypotensive effect. - Diuretics: may increase risk of orthostatic hypotension. - Statins metabolized by CYP3A4 (e.g., simvastatin): may require dose adjustment.